BroadOak Capital Partners advised Biosynth on the acquisition of celares GmbH.  Celares provides customized bioconjugation solutions

Genomenon, a BroadOak portfolio company and a leader in genomic intelligence, acquired Boston Genetics, a genomics

BroadOak Capital Partners invested in Indee Labs out of its BioTools Venture Fund to support the

Sanguine is a leader in custom specimen procurement used by biopharmaceutical companies to accelerate precision medicine

BroadOak invested in CDI Labs, a provider of serological biomarker discovery services and monoclonal antibody manufacturing

BroadOak portfolio company PBS Biotech, an innovative manufacturer of single-use bioreactors, has completed a $22 million

BroadOak portfolio company PhenoVista Biosciences, a leading provider of both custom and off-the-shelf imaging-based assay services,

BioCare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) and FISH (Fluorescent in situ hybridization)

BroadOak partnered with United BioChannels (UBC) to acquire ORFLO Technologies (ORFLO) in October 2022. ORFLO, a